Where the Street stands
These are third-party analyst opinions from named firms, not advice, and not a prediction. Earnings land in 8 days, which usually moves targets. How we score this
21 firms currently rating it, weighted by track record.
The 20 firms with a track record here beat the S&P 41% of the time over 12 months.
Pro: see the crowd-vs-sharp split for LLYTwenty-seven analysts rate Eli Lilly a Buy or stronger, with an average price target of $1270.37, implying 10.8% upside from current levels. Recent actions have been uniformly constructive: Citigroup, Bernstein, UBS, Guggenheim, and BofA Securities all maintained buy-equivalent ratings in mid-July. The pharma giant is delivering exceptional growth, with revenue up 55.50% year-over-year and EPS up 169.90%, while maintaining a 34.99% net margin and generating a 107.46% return on equity. The stock trades at a 41.84 trailing P/E but 25.54 forward P/E, and has climbed from a 52-week low of $623.78 to approach its $1249.45 high.
Generated from the data on this page; may contain errors. Analyst opinions belong to the named firms. Informational only, not investment advice.
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jul 15, 2026 | Citigroup | ○ Maintained | |
| Jul 14, 2026 | Bernstein | ○ Maintained |
Create a free account to unlock all analyst ratings, key stats, and news. No credit card, takes 30 seconds.
Sign up free